Low-Dose Naltrexone for Cancer: Case Series and Human Studies (2026)

Introduction: Can Low-Dose Naltrexone (LDN) Play a Role in Cancer Treatment?

Low-dose naltrexone (LDN) has emerged as one of the most discussed repurposed drugs in integrative oncology—drawing attention from researchers, clinicians, and patients seeking safer, adjunctive cancer therapies. Originally developed as a high-dose medication to treat opioid and alcohol dependence, naltrexone behaves very differently when used at much lower doses (typically 1–5 mg daily), triggering unique biological effects that may influence cancer biology.

Unlike conventional chemotherapy, which directly targets rapidly dividing cells, LDN appears to work through indirect mechanisms—modulating the immune system, altering inflammatory pathways, and influencing cellular signaling involved in tumor growth. One of the most studied mechanisms involves the opioid growth factor (OGF)–opioid growth factor receptor (OGFr) axis, a regulatory pathway that plays a key role in controlling cell proliferation. By transiently blocking this pathway, LDN may stimulate a rebound increase in endogenous OGF, which has been shown to inhibit cancer cell growth and replication in preclinical models. (LDN Research Trust)

In addition to its effects on the OGF–OGFr axis, LDN has been associated with broader immunomodulatory actions, including enhancement of anti-tumor immune responses and reduction of pro-inflammatory signaling pathways. Experimental studies suggest that LDN may promote cancer cell apoptosis (programmed cell death), inhibit tumor invasion, and improve immune surveillance—effects observed across multiple cancer types such as colorectal, cervical, and breast cancers. (LDN Research Trust)

Importantly, LDN is not considered a standalone cure for cancer. Instead, its greatest potential may lie as an adjunct therapy, used alongside conventional treatments like chemotherapy, immunotherapy, or targeted therapy. Its low cost, favorable safety profile, and lack of direct cytotoxicity make it particularly appealing in integrative and personalized cancer care strategies. (LDN Research Trust)

However, despite promising laboratory and early clinical data, high-quality large-scale randomized controlled trials are still limited. Much of the current interest in LDN is driven by preclinical evidence, small studies, and anecdotal reports, underscoring the need for more rigorous research before definitive clinical recommendations can be made.

This article explores the science, evidence, mechanisms, and real-world considerations behind low-dose naltrexone in cancer—helping patients and clinicians understand where it fits in the evolving landscape of oncology.

Human Case Reports

Published case reports describe striking outcomes in patients with advanced cancer who used LDN, though none of these can establish causation on their own.

Pancreatic cancer: Berkson et al. reported multiple patients with stage IV pancreatic adenocarcinoma and liver metastases treated with LDN at 4.5 mg once daily combined with intravenous alpha-lipoic acid. One patient was alive 78 months after diagnosis — a disease with a typical prognosis of 3 to 6 months. Two additional patients achieved PET-confirmed radiological remission. After stopping the protocol, one of these patients relapsed within a month (Berkson et al., 2006; Berkson et al., 2009).

B-cell lymphoma: A 61-year-old man with biopsy-proven follicular lymphoma, stage III, refused conventional chemotherapy (I am not recommending this!) and was treated with LDN 3 mg daily only. Within 6 months, all pathological lymph nodes — including baseball-sized nodes in the cervical region and left groin — showed complete resolution on PET/CT imaging. The patient reported remaining symptom-free one year after his last imaging (Berkson et al., 2007).

Tongue cancer (adenoid cystic carcinoma): A 58-year-old man with T4N0M0 adenoid cystic carcinoma of the tongue base who refused the recommended surgical removal was treated with LDN at 3 to 4 mg daily plus vitamin D3 at 10,000 IU daily. He achieved long-term remission (Khan, 2014).

Lung cancer: A 50-year-old male with non-small cell lung cancer and a history of prostate cancer experienced prolonged survival while using LDN among other medications (Miskoff & Chaudhri, 2018).

Renal cell carcinoma: A 64-year-old with stage IV renal cell carcinoma had stable disease with disappearance of signs and symptoms for 9 years following an integrative approach that included LDN at 4.5 mg at bedtime combined with IV alpha-lipoic acid (Berkson, 2018).

Prostate cancer: Dalgleish and Liu reported a case series of 6 prostate cancer patients managed with immune modulation including LDN as part of a multi-agent approach (Dalgleish & Liu, 2022).

Human Clinical Trials

There are no large placebo-controlled randomized controlled trials (RCT) of true low-dose naltrexone (1.5–5 mg) for cancer outcomes in any cancer type, likely owing to the structural problems around generic drug development discussed above.

The only placebo-controlled, double-blind RCT is a Duke University glioma trial (Peters et al., 2022) which looked at the effect of LDN on quality of life (QoL) and fatigue during concurrent chemotherapy and radiation, not cancer outcomes. While it found no statistically significant difference in QoL or fatigue between LDN and placebo groups, the researchers noted that LDN may have allowed a meaningful “clinical” difference in fatigue post concurrent radiation therapy and chemotherapy. The study was not designed or powered to evaluate cancer survival as an endpoint, but noted that the LDN median survival was 20.9 months vs placebo 18.1 months (difference not statistically significant). Crucially, the adverse event profiles were indistinguishable between LDN and placebo, and the two grade 5 (fatal) adverse events in the trial both occurred in the placebo arm—demonstrating a remarkable safety profile of LDN.

Two smaller human studies — the 2025 MD Anderson cancer pain case series (20 cancer patients, LDN 1.5–4.5 mg) and the 2014 metabolic treatment case series (10 patients with chemo-resistant metastatic cancers, LDN 4.5–5 mg at bedtime) — both also confirmed that LDN was safe and well tolerated, with no serious adverse events attributable to LDN. The MD Anderson series found an 80% positive response rate for cancer pain at first follow-up, with particular benefit in patients with neuropathic pain.

In the metabolic treatment case series, ten patients with chemoresistant advanced metastatic cancer and life expectancy of 2-6 months were treated with a combination of lipoic acid, hydroxycitrate, and LDN (5 mg). Most patients achieved disease stabilization or slowed progression, though two patients died of progressive disease within two months. The authors noted that the results suggest the probable efficacy of metabolic treatment in chemoresistant advanced carcinoma and/or enhancement of chemotherapy efficacy. Caveat: This case series involved a combination of metabolic treatments, so the effects cannot be attributed solely to LDN.

A Phase I study is also underway evaluating naltrexone plus propranolol in combination with standard immunotherapy in patients with advanced melanoma (ClinicalTrials.gov: NCT05968690).

Outside of cancer, LDN has separately exhibited potential use in human trials or case studies for other diseases that have a component of immune dysregulation and/or inflammation, e.g. multiple sclerosis, Crohn’s disease, fibromyalgia, HIV, autoimmune thyroid disease, hyperinsulinemia-related insulin resistance, Sjogren’s syndrome, psoriasis, Stiff-Person syndrome, and Long Covid.

Safety: The Consistent Finding Across ALL Studies

Across every study — whether LDN showed anti-cancer benefit or not — it was safe and well tolerated at 1.5 to 4.5 mg doses. LDN is non-addictive — it is an opioid antagonist, not an agonist — so it carries no abuse potential.

Side effects reported across clinical trials in cancer and non-cancer conditions are consistently mild and transient: vivid dreams (not usually reported as unpleasant), transient headache, and brief insomnia during the first few days after initiation.

There is a breast cancer phase II trial worth noting here as well, though it used standard-dose naltrexone (escalated from 10 to 25 to 50 mg daily), not low dose naltrexone. Even at this much higher dose, naltrexone had an excellent safety profile. The study showed only modest anti-cancer activity — one partial response out of eight evaluable patients. The limited efficacy at standard dose is consistent with the broader literature's emphasis that brief, intermittent receptor blockade — not continuous high-dose blockade — is what drives anti-cancer effects.

Discussion

The Cancer Pain Angle: A Practical Entry Point

If you are a cancer patient interested in trying LDN, the most practical way to start the conversation with your oncologist may not be to lead with “I want to try an anti-cancer drug”, but rather to frame it as a pain or fatigue management discussion.

LDN is already used off-label for a range of chronic non-cancer pain conditions, including fibromyalgia, complex regional pain syndrome (CRPS), and neuropathic pain, with published evidence supporting its use in these settings.

A Script for Your Doctor

If you’d like to raise LDN with your doctor, here is a template you can adapt and send to your doctor before your appointment. When advocating for yourself, it’s always best to first send requests in writing and then follow up with discussion at your appointment. (datadosing.substack.com)

“Dear Dr. [Name],

I’d like to discuss trying low-dose naltrexone (LDN) as an addition to my current treatment plan. I’ve been reading published peer-reviewed research on this and wanted to share a few points:

LDN refers to naltrexone at doses of 1.5 to 4.5 mg taken once daily — much lower than the standard 50 mg dose used for addiction. At this low dose, naltrexone has a mechanism that is fundamentally different from, and in some respects opposite to, the continuous receptor blockade produced by the standard dose.

A 2025 case series from MD Anderson Cancer Center (Malik et al., Journal of Pain and Symptom Management) found that LDN was safe and showed an 80% positive response rate for refractory cancer-related pain, with only minor side effects.

A 2022 placebo-controlled, double-blind, randomized trial in 110 high-grade glioma patients at Duke (Peters et al., Supportive Care in Cancer) found that LDN’s adverse event profile was indistinguishable from placebo over 16 weeks. No serious adverse events were attributed to LDN.

Multiple review papers — including Ciwun et al. (Cancers, 2024), Liu & Dalgleish (Expert Review of Anticancer Therapy, 2022), and Liubchenko et al. (Advances in Therapy, 2021) — summarize robust preclinical evidence for anti-cancer properties of LDN as well in a wide range of cancers (e.g. ovarian, colon, breast, lung, prostate, glioblastoma, neuroblastoma, melanoma, liver, gastric, lymphoma, leukemia, renal, sarcoma, thyroid), though clinical trial data remains limited. There are also several published case reports (see Berkson, 2007-2010) of notable outcomes in patients with advanced cancer using LDN. I understand these are anecdotal case reports, not controlled trials, but they are published in peer-reviewed journals and consistent with the preclinical evidence.

I also understand this is off-label and that the evidence for anti-cancer effects is still preliminary. I’m primarily interested in it for [pain management / as a low-risk adjunct / quality of life]. Given its favorable safety profile and low cost, would you be open to a trial of LDN starting at 1.5 mg nightly?

I’m not currently on any opioid pain medications [OR: I understand the timing would need to be coordinated with my current pain medications].

I’m happy to share the published papers with you if that would be helpful.”

LDN can be easily obtained from Telehealth providers that use compounding pharmacies (e.g. Midi, AgelessRx); but please see Cautions below and never add a medication from another healthcare provider without also informing your Primary Care Provider and/or Oncologist.

Compounding Pharmacies

LDN must be compounded, meaning even if the prescription comes from Stanford Hospital (commonly used in their Long Covid clinic) or another reputable medical institution, it still needs to go through a compounding pharmacy. Compounded medications bypass the standard FDA review process, which carries a higher risk of potency errors and contamination—especially with injectables where sterility is non-negotiable (e.g. peptides can be high risk—more on this in a later post!).

So, when a provider prescribes a compounded medication, you should verify that the pharmacy is PCAB-accredited (Pharmacy Compounding Accreditation Board), which serves as the gold standard for safety and quality in the industry, and ensure the facility is a 503A or 503B pharmacy (503B look up here). Any provider using a compounding pharmacy should also be able to answer these questions regarding the pharmacy they use. (datadosing.substack.com)

Conclusion: Where Does Low-Dose Naltrexone Fit in Modern Cancer Care?

Low-dose naltrexone (LDN) represents a compelling example of drug repurposing in oncology—offering a low-cost, generally well-tolerated intervention with biologically plausible anti-cancer mechanisms. Through modulation of the opioid growth factor (OGF)–OGF receptor axis, immune system regulation, and anti-inflammatory effects, LDN has demonstrated encouraging signals in preclinical studies and early clinical observations across multiple cancer types.

However, it’s important to remain grounded in the current level of evidence. While laboratory data and small-scale human studies suggest potential benefits—including slowed tumor growth, improved immune surveillance, and enhanced quality of life—LDN has not yet been validated in large, high-quality randomized controlled trials. As such, it should not be viewed as a replacement for established cancer treatments such as surgery, chemotherapy, radiotherapy, or immunotherapy.

Instead, the most rational role for LDN today is as an adjunctive therapy within an integrative oncology framework. Under appropriate medical supervision, it may be considered alongside standard treatments, particularly for patients seeking additional immune support, better tolerability, or complementary strategies that align with personalized care goals.

Safety is another key advantage. At low doses, naltrexone is generally well tolerated, with mild and transient side effects in most patients. This favorable safety profile, combined with its affordability and accessibility, has contributed to its growing interest among both patients and forward-thinking clinicians.

Looking ahead, the future of LDN in oncology will depend on more rigorous clinical research. Well-designed trials are needed to clarify optimal dosing, identify which cancer types may benefit most, and determine how LDN interacts with modern therapies such as immune checkpoint inhibitors and targeted treatments.

In summary, LDN sits at the intersection of promise and uncertainty. It is not a miracle cure—but neither should it be dismissed. For informed patients and clinicians willing to explore evidence-based integrative approaches, LDN may offer a meaningful addition to the broader cancer treatment landscape.

Source and Reference: https://datadosing.substack.com/p/could-a-cheap-generic-drug-improve.

Important Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with your oncologist or medical team before making changes to your treatment plan.

Available on Amazon